## Blockade of Interleukin 27 Signaling Attenuates Graft Versus Host Disease By Augmenting CD4<sup>+</sup> and CD8<sup>+</sup> Regulatory T Cell Reconstitution

**Ludovic Belle, PhD**<sup>1\*</sup>, Kimberle A. Agle, PhD<sup>1\*</sup>, Vivian Zhou, PhD<sup>1\*</sup>, Vanessa Yuan, MS<sup>1\*</sup>, Jie Sun, PhD<sup>2\*</sup>, Nico Ghilardi, PhD<sup>3\*</sup>, Jacques van Snick, PhD<sup>4\*</sup> and William R. Drobyski, MD<sup>1</sup>

<sup>1</sup>Medical College of Wisconsin, Milwaukee, WI; <sup>2</sup>Indiana University School of Medicine, Indianapolis, IN; <sup>3</sup>Genentech, Inc, South San Francisco, CA; <sup>4</sup>Ludwig Cancer Institute, Brussels, Belgium

The interleukin-6 (IL-6) cytokine superfamily (i.e. IL-6, IL-12, and IL-23) plays a major role in the modulation of inflammatory and regulatory pathways during graft versus host disease (GVHD). IL-27, a recently discovered member of this family, is a heterodimeric cytokine that is composed of the p28 and EBI3 subunits and signals through a heterodimeric receptor composed of WSX-1 and gp130. Notably, IL-6 also uses gp130 as a signaling component which biologically links IL-27 and IL-6. IL-27 has been shown to have opposing proinflammatory and immunoregulatory effects, but its role in GVHD is not well understood. To define the functional significance of IL-27, lethally irradiated Balb/c (H-2<sup>d</sup>) mice were transplanted with C57BL/6J (H-2<sup>b</sup>) BM and spleen cells, and then treated with an anti-IL-27p28-specific antibody on days 0 and +6. p28 antibody-treated animals had significantly improved weight recovery and overall survival (47% versus 0% survival at day 60, p=0.002), as well as reduced numbers of proinflammatory CD4<sup>+</sup> and CD8<sup>+</sup> IFN-γ<sup>+</sup> T cells in GVHD target organs, when compared to isotype control antibodytreated mice. A similar outcome was observed in an MHC-matched, minor antigen disparate model (B6→Balb.B), indicating that this was not a strain-specific phenomenon. Given the similarities between IL-6 and IL-27, we examined whether blockade of IL-27 promoted regulatory T cell (Treg) reconstitution as has been observed with inhibition of IL-6 signaling. Recipients transplanted with BM grafts from B6 Foxp3 FGFP reporter animals and treated with p28 antibody had a significant increase in the number of CD4<sup>+</sup> nTregs, CD4<sup>+</sup> iTregs and CD8<sup>+</sup> iTregs in GVHD target organs, indicating that blockade of IL-27 augmented global Treg reconstitution. In fact, inhibition of IL-27 was more effective at augmenting Treg reconstitution than comparable antibody blockade of IL-6. To further elucidate the role of IL-27, we employed transgenic IL-27<sup>-/-</sup> and IL-27R<sup>-/-</sup> animals to dissect the relevant contributions of donor and recipient populations. Paradoxically, we observed that transplantation with IL-27<sup>-/-</sup> donor grafts exacerbated GVHD mortality and augmented accumulation of proinflammatory T cells, whereas transplantation of recipient IL-27<sup>-/-</sup> mice with wild type grafts had no effect on transplant outcomes. This discordance between antibody-based and genetic studies was unexpected and led us to consider whether there were steady state alterations in T cells from IL-27<sup>-/-</sup> animals that biased these cells towards a proinflammatory phenotype. To that end, we observed that naive CD8<sup>+</sup> T cells from IL-27<sup>-/-</sup> mice had greater IFN-y production than wild type cells after in vitro polyclonal stimulation and CD4<sup>+</sup> nTregs from these animals had diminished expression of CXCR3 which is critical for Treg trafficking into inflamed tissue sites. Thus, the lack of endogenous IL-27 resulted in intrinsic immune dysregulation which led to an exacerbation of GVHD after transfer of these T cells into recipients. To resolve this paradox, we employed IL-27R<sup>-/-</sup> (WSX-1<sup>-/-</sup>) mice and demonstrated that mice transplanted with IL-27R<sup>-/-</sup> grafts had enhanced weight recovery and survival providing confirmation that blockade of IL-27 signaling reduced GVHD. In addition, using IL-27R<sup>-/-</sup>Foxp3<sup>EGFP</sup> reporter mice, we observed increased frequencies and numbers of CD4<sup>+</sup> and CD8<sup>+</sup> Foxp3<sup>+</sup> T cells in mice reconstituted with IL-27R<sup>-/-</sup> grafts, confirming results observed with p28 antibody blockade. Since IL-10 is a mechanism by which CD4<sup>+</sup> Tregs suppress GVHD and IL-27 has been shown to enhance T cell-derived IL-10 secretion in nontransplant models, we examined whether IL-27 blockade adversely affected IL-10 production by Tregs. Recipients transplanted with marrow grafts from IL-10.BitFoxp3<sup>EGFP</sup> dual reporter animals and treated with p28 antibody had a significant reduction in the frequency of IL-10-producing conventional CD4<sup>+</sup> and CD8<sup>+</sup> T cells in GVHD target organs. Notably, however, there was no difference in the frequency of CD4<sup>+</sup> Foxp3<sup>+</sup> IL-10<sup>+</sup> T cells, indicating that blockade of IL-27 signaling preferentially affected conventional T cells and had no adverse effect on CD4<sup>+</sup> Foxp3<sup>+</sup> T cell-derived IL-10 production. In summary, these studies demonstrate that blockade of IL-27 signaling potently augments Treg reconstitution leading to a reduction in the severity of GVHD and may therefore represent a novel strategy to reduce mortality from this disease in man.

Abstract ID#: 77936

Review Category Selection: 702. 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-

**Tumor Effects** 

Is the first author/presenter of this abstract a hematologist in training?: Yes

Hematologist in training: Yes

Status: Post Doctoral (MD or PhD) Fellow